Investigative Research from Japan Reveals: COVID-19 Vaccines Employ Autonomous Nanotechnology | Long-Term Monitoring of Vaccine Effects for 12 Months + Examination of Cellular Toxicity
In a groundbreaking study, researchers Dr Young Mi Lee and Dr Daniel Broudy have delved into the cellular effects of the Pfizer-BioNTech and Moderna COVID-19 vaccines, uncovering intriguing findings about the self-assembly nanotechnology within these vaccines.
This study, one of the most comprehensive and long-term to date, has shed light on the presence of nanotechnology in the vaccines. The observations suggest the presence of artificial self-assembling entities, ranging from 1 to 100 μm, in the vaccines. These entities, visible to the naked eye and stereoscopically visible, took various shapes, including worm-like structures, discs, chains, spirals, tubes, and right-angle structures.
The entities were observed to self-assemble over time during incubation, with simple structures becoming more complex and developing into three-dimensional entities. Some structures appeared and then disappeared over time. The findings of this study are consistent with prior research on self-assembly nanotechnology from the vaccines.
The study, which included incubation of the vaccines and examination of their effects on blood and semen specimens, was conducted using images from a 66-page long article. The entities observed were not previously mentioned in the earlier research on these vaccines.
The self-assembly nanotechnology in the Pfizer-BioNTech and Moderna COVID-19 vaccines is based on lipid nanoparticles that are precisely engineered for mRNA encapsulation, protection, and delivery. The lipid nanoparticles, or LNPs, are formed by self-assembly of lipid components in an aqueous environment, creating stable particles that encapsulate mRNA effectively.
Cholesterol, phospholipids, and PEGylated lipids contribute to nanoparticle stability, biodistribution, and immune response modulation. Optimization of these components can influence immunogenicity and adverse reactions. For instance, shorter PEG chains and altered cholesterol sources can boost immune response while reducing side effects.
The stability of these LNPs is crucial for vaccine efficacy. Moderna’s LNPs typically require storage at −25 to −15°C, whereas Pfizer’s require colder storage at −90 to −60°C. Recent novel formulations show potentially improved stability at higher temperatures compared to current Pfizer and Moderna LNPs, which might prolong shelf life and ease distribution challenges.
The self-assembled LNPs enable efficient cellular uptake and mRNA delivery, leading to robust antigen expression and immune activation. Studies report that modulation of lipid components can fine-tune protein expression levels and reduce systemic inflammation and reactogenicity, indicating a nuanced control afforded by lipid nanotechnology.
The authors of the study encourage wide sharing of the findings to foster further discussion and research in this area. The study is available for download at the provided link. It's important to note that this article provides factual information based on the given bullet points and does not express any opinions or unrelated information.
- The groundbreaking study by Dr Young Mi Lee and Dr Daniel Broudy has revealed the presence of self-assembly nanotechnology in the Pfizer-BioNTech and Moderna COVID-19 vaccines.
- This study, which includes observations of artificial self-assembling entities in the vaccines, has not been previously mentioned in earlier research.
- The self-assembly nanotechnology in these vaccines is based on lipid nanoparticles (LNPs) that are precisely engineered for mRNA encapsulation, protection, and delivery.
- The findings of the study suggest that the self-assembly of these nanoparticles leads to the formation of entities visible to the naked eye, which take various shapes.
- The study also highlights the importance of optimizing the components of these LNPs, such as cholesterol, phospholipids, and PEGylated lipids, for vaccine efficacy, immune response, and reducing adverse reactions.
- The self-assembled LNPs enable efficient cellular uptake and mRNA delivery, potentially leading to improved vaccine efficacy and reduced distribution challenges, as indicated by recent novel formulations.
